RepurpOS

Sjögren's Syndrome

Disease intelligence for Sjögren's Syndrome: 10 alterations and 0 ranked therapeutics from curated public databases.

US DALYs1.70MWHO GHE 2021 · all ages
Global DALYs13.92MWHO GHE 2021 · worldwide
US mortality57.7K deaths/yrWHO GHE 2021
Global mortality221.3K deaths/yrWHO GHE 2021 · worldwide
NIH funding$30MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remissionChronic and progressive; glandular dysfunction (dry eyes/mouth) irreversible in most; fatigue and systemic features…
Best-intervention remissionHydroxychloroquine: limited systemic benefit; rituximab: parotid gland improvement and fatigue in some trials but…
Gap sizeVery large — no approved disease-modifying therapy; symptomatic management only for glandular features
Primary barrierbiological + access
Full remission profile →

Disease overview

Alterations
10
Molecular (A)
0
Clinical (B–E)
10
Direct drugs
0
Via biomarker
0
Natural agents
0
Natural products
18
Merged ranked
0

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, GreenMedInfo, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission
Chronic and progressive; glandular dysfunction (dry eyes/mouth) irreversible in most; fatigue and systemic features fluctuate; lymphoma risk 5-15x general population; spontaneous full remission rare
Best-intervention remission
Hydroxychloroquine: limited systemic benefit; rituximab: parotid gland improvement and fatigue in some trials but primary endpoint failure in Phase 3 (TEARS, TRACTISS); no disease-modifying therapy approved; best outcomes with early systematic sicca management
Drug-free remission
Relapse after remission
Chronicity
Gap size
Very large — no approved disease-modifying therapy; symptomatic management only for glandular features
Primary barrier
biological + access
Barrier detail: Sjögren's research has been hampered by heterogeneous disease and lack of validated endpoints; rituximab failed multiple Phase 3 trials despite positive Phase 2 data (endpoint selection problem); anti-Ro/SSA positivity enriches trials but treatment effects still modest; diagnosis itself is delayed 4-7 years on average

Last SoC change: 2023 — iscalimab (anti-CD40) Phase 3 data; no disease-modifying therapy approved; EULAR recommendations updated 2020; hydroxychloroquine as standard systemic agent since 1990s

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: —

Alterations

10 total · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
Change in corneal / conjunctival staining score using the National Eye Institute/Industry(NEI) Industry Grading System Scales & PROs Clinical scale Emerging ClinicalTrials.gov
ESSDAI Lab / Clinical Lab value Emerging ClinicalTrials.gov
EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Health assessment questionnaire (HAQ) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Number of Participants With Adverse Events (AEs) Lab / Clinical Lab value Emerging ClinicalTrials.gov
Ocular Surface Disease Index (OSDI) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA Lab / Clinical Lab value Emerging ClinicalTrials.gov
Pittsburgh Sleep Quality Index Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Visual Analog Scale (VAS) Scales & PROs Clinical scale Emerging ClinicalTrials.gov
Xerostomia Inventory Lab / Clinical Lab value Emerging ClinicalTrials.gov

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

No therapeutics in this section.

No therapeutics in this section.

No therapeutics in this section.

Natural Products

18 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Omega-3 Fatty Acids Natural product Nutraceutical Phase III Emerging 10
1 trials
View evidence

Registry trials

  • NCT05005806 — Fish Oil (Omega 3 ) in Sjogren's Syndrome (COMPLETED) PHASE2, PHASE3

GreenMedInfo
Curcumin Natural product Food compound Preclinical Emerging 7
5 pubs
View evidence

Published literature

GreenMedInfo
Egcg Natural product Food compound Preclinical Emerging 7
9 pubs
View evidence
GreenMedInfo
Lactobacillus Natural product Probiotic Preclinical Emerging 7 GreenMedInfo
Melatonin Natural product Nutraceutical Preclinical Emerging 7
6 pubs
View evidence
GreenMedInfo
Peony Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product Nutraceutical Preclinical Emerging 0
No indexed hits
View evidence
GreenMedInfo
Paeoniflorin Natural product Nutraceutical Preclinical Emerging 0
18 pubs
View evidence
GreenMedInfo
Essential Fatty Acids Natural product Nutraceutical Preclinical Emerging 0
2 RCT
View evidence

Published literature

GreenMedInfo
Colostrum Natural product Nutraceutical Preclinical Emerging 0
3 pubs
View evidence
GreenMedInfo
Cardamonin Natural product Nutraceutical Preclinical Emerging 0
1 Trial pubs
View evidence

Published literature

GreenMedInfo
Dhea (Dehydroepiandrosterone) Natural product Nutraceutical Approved Emerging 0
2 trials
View evidence

Registry trials

  • NCT00543166 — Sex Steroids in Sjögren's Syndrome: Effect of Substitution Treatment on Fatigue (UNKNOWN) PHASE4
  • NCT00391924 — Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome (COMPLETED) PHASE2

GreenMedInfo
Pycnogenol (Pine Bark) Natural product Nutraceutical Preclinical Emerging 0
No indexed hits
View evidence
GreenMedInfo
Flavonoids Natural product Nutraceutical Preclinical Emerging 0
3 pubs
View evidence
GreenMedInfo
Verbascoside Natural product Nutraceutical Preclinical Emerging 0
No indexed hits
View evidence
GreenMedInfo
Blueberry Natural product Nutraceutical Preclinical Emerging 0
2 pubs
View evidence
GreenMedInfo
Goji Natural product Nutraceutical Preclinical Emerging 0
1 pubs
View evidence
GreenMedInfo
Isoflavones Natural product Nutraceutical Preclinical Emerging 0
No indexed hits
View evidence
GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
VitalScan4PACVS Remote physiological monitoring study for post-acute COVID-19 vaccination syndrome.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.